You are here
Home > Treatment Approaches > Medication

FDA Removing Black Box Warnings on Smoking Cessation Drugs

December 19, 2016 Share this content: Varenicline and bupropion pose a lower risk of serious mental health side effects than was previously thought. Following a required clinical trial review1, the US Food and Drug Administration (FDA) has determined that 2 smoking cessation drugs, varenicline(Chantix®, Pfizer)  and bupropion (Zyban®, GlaxoSmithKline), are associated with a

Depression Medication Linked to Increased Risk of ICH

December 19, 2016 This article originally appeared on Neurology Advisor. Share this content: Caution should be taken when prescribing high-strength SSRIs, particularly in combination with anticoagulant therapies. Risk of intracranial hemorrhage (ICH) associated with selective serotonin reuptake inhibitors (SSRIs) increases with the strength of the agent used (ICH), according to results from a large-scale

Switching Antidepressants During Nonresponse May Be Ineffective

December 14, 2016 Share this content: Adults with major depressive disorder who are nonresponsive to treatment may not benefit from switching antidepressant. One of the biggest challenges in assessing the treatment of major depression is antidepressant effectiveness. All antidepressants share a high rate of nonresponse, which often leads clinical practitioners to switch the

Link Between Antidementia Drug Use and Pneumonia Examined

December 12, 2016 This article originally appeared on Infectious Disease Advisor. Share this content: The risk of developing pneumonia is higher among patients who use antidementia drugs. Patients with Alzheimer's disease undergoing monotherapy with memantine have a higher risk of pneumonia than patients using donepezil, according to research published in the Annals of Medicine. Investigators

Efficacy of Lurasidone Assessed in Adolescents With Schizophrenia

November 14, 2016 This article originally appeared on MPR. Share this content: Sunovion have announced positive results from a study evaluating Latuda (lurasidone HCI) for the treatment of schizophrenia in adolescents aged 13 to 17 years old. A double-blind, placebo-controlled six week study randomized 285 adolescents with schizophrenia to receive fixed doses of Latuda

Predicting Placebo Response May Now be Possible

November 10, 2016 This article originally appeared on Clinical Pain Advisor. Share this content: Connectivity in the right midfrontal gyrus may help predict placebo response. This finding has widespread implications in drug development. Connectivity in the right midfrontal gyrus may help predict placebo response, according to a study published on October 27 in PLOS Biology.1 This

Schizophrenia Drug Reduces Migraine Severity

October 25, 2016 This article originally appeared on Neurology Advisor. Share this content: Eighty-one percent of patients deemed ziprasidone effective in reducing migraine severity.  An atypical antipsychotic used to treat schizophrenia may also serve as a rescue medication in patients with status migrainosus. The findings were published in The Neurohospitalist.1  Patients diagnosed as having status